Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding

Radoslaw Wasiak, Anna Filonenko, David J. Vanness, Amy Law, Mark Jeddi, Kim U Wittrup-Jensen, Kim Wittrup‐Jensen, Donald E. Stull, Steven Siak, Jeffrey T. Jensen
Journal of women's health (2002) · 2013 · vol. 22(4) , pp. 378–384 · doi:10.1089/jwh.2012.3633 · PMID:23586801 · W2067183284
RCT OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Estradiol valerate/dienogest treatment significantly improved work productivity and daily living activities in North American women with heavy menstrual bleeding compared to placebo, with associated monetary benefits.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To quantify the change in work productivity and activities of daily living in North American women with heavy menstrual bleeding (HMB) treated with estradiol valerate/dienogest (E2V/DNG; Qlaira(®)/Natazia(®)) compared to placebo. METHODS: Women in the United States and Canada, aged 20-53 years with an objective diagnosis of HMB and no recognizable anatomical pathology, were treated with E2V/DNG or placebo for seven cycles (196 days). Main outcome measures included work productivity (i.e., productivity while at work) and activities of daily living measured using a modified Work Productivity and Activity Impairment Questionnaire (mWPAI) on a Likert scale from 0 to 10 (higher values denote higher impairment levels). RESULTS: In both countries, significant improvement was observed between baseline and end of treatment in work productivity and activities of daily living impairment. The improvements in work productivity and activities of daily living with E2V/DNG treatment relative to placebo ranged from 37.2% to 39.2% across both countries. Monthly gains due to E2V/DNG treatment (net of placebo improvement) associated with improvement in work productivity were estimated to be US$80.2 and Can$70.8 (US$58.5) and those associated with improvement in activities of daily living were estimated to be US$84.9 and Can$73.5 (US$60.7). CONCLUSIONS: E2V/DNG was shown to have a consistent positive impact on work productivity and activities of daily living in U.S. and Canadian women with HMB. In addition, these improvements in work productivity and activities of daily living were associated with a reduction in HMB-related monetary burden compared to the placebo group.

My notes (saved in your browser only)

MeSH descriptors

Activities of Daily Living Contraceptives, Oral, Hormonal Estradiol Menorrhagia Nandrolone Work Adult Contraceptives, Oral, Hormonal Double-Blind Method Drug Combinations Efficiency Estradiol Estradiol Female Humans Menorrhagia Middle Aged Nandrolone Nandrolone Treatment Outcome

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (35)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-11T05:18:01.733872+00:00
pubmed
last seen: 2026-10-08T21:11:51.557491+00:00
License: CC0 · commercial use OK